Perrigo Plc (PRGO) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Perrigo Company Plc  (NYSE: PRGO)


Perrigo Plc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRGO Gross Profit Margin (Sep 26 2026)
Q3 		(Jun 27 2026)
Q2 		(Mar 28 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 27 2025)
Q3
Y / Y Revenue Change -5.22 %
Seq. Revenue Change -3.34 %
Revenue In Millions $988.60
Gross Profit Margin 32.45 %
Gross Profit Margin Total Ranking # 2362
Gross Profit In Millions $320.80
Y / Y Gross Profit Change -14.93 %
Seq. Gross Profit Change 2.2 %


Commenting Third Quarter 2026 Gross Profit Margin
Perrigo Company Plc achieved Gross Profit of $321 millions compare to Gross Loss of $313.90 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q3 of -3.34 % Perrigo Company Plc managed to reduce Cost of Sales and increase Gross Profit by 2.2 % to $321 millions. Gross Profit Margin grew to 32.45 %, below company average Gross Profit Margin.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2362, from total ranking in the previous quarter at 2644.
Learn about Gross Margin
PRGO's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 129
Healthcare Sector # 372
Overall # 2342

Gross Profit Margin Statistics
High Average Low
43.11 % 36.35 % 30.69 %
(Sep 26 2015)   (Jun 27 2026)


PRGO Gross Income Trends • More of PRGO's Profitabilty Ratios • PRGO Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PRGO's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PRGO's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PRGO's Competitors
Gross Profit Margin Profit Margin for Perrigo Plc's Suppliers
Gross Profit Margin Profit Margin for PRGO's Customers

You may also want to know
PRGO's Annual Growth Rates PRGO's Profitability Ratios PRGO's Asset Turnover Ratio PRGO's Dividend Growth
PRGO's Roe PRGO's Valuation Ratios PRGO's Financial Strength Ratios PRGO's Gross Profit Growth
PRGO's Roa PRGO's Inventory Turnover Ratio PRGO's Growth Rates PRGO's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 26 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 26 2026 MRQ Gross ProfitSep 26 2026 MRQ Revenue
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Ocular Therapeutix Inc   88.70 %$ 11.419  Millions$ 12.874  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions
Aclaris Therapeutics Inc   87.24 %$ 1.292  Millions$ 1.481  Millions
Ligand Pharmaceuticals Incorporated  87.04 %$ 68.541  Millions$ 78.746  Millions
Liquidia Corporation  86.88 %$ 195.746  Millions$ 225.300  Millions
Rhythm Pharmaceuticals Inc   86.79 %$ 79.962  Millions$ 92.128  Millions
Rigel Pharmaceuticals Inc  86.67 %$ 70.107  Millions$ 80.890  Millions
Newamsterdam Pharma Company N v   86.11 %$ 16.503  Millions$ 19.164  Millions
Indivior Pharmaceuticals Inc   85.67 %$ 305.000  Millions$ 356.000  Millions
Insmed Inc  85.09 %$ 446.213  Millions$ 524.428  Millions
Vertex Pharmaceuticals Inc  84.71 %$ 2,914.700  Millions$ 3,440.800  Millions
Eli Lilly And Company  83.88 %$ 20,464.000  Millions$ 24,397.000  Millions
Tg Therapeutics Inc   83.81 %$ 217.857  Millions$ 259.936  Millions
Akebia Therapeutics Inc   82.76 %$ 30.541  Millions$ 36.903  Millions
Renovorx Inc   82.36 %$ 0.878  Millions$ 1.066  Millions
Alkermes Plc   80.38 %$ 385.912  Millions$ 480.132  Millions
Biomarin Pharmaceutical Inc  79.95 %$ 819.230  Millions$ 1,024.646  Millions
Innoviva Inc   79.52 %$ 84.382  Millions$ 106.120  Millions
Pacira Biosciences inc   78.92 %$ 139.420  Millions$ 176.653  Millions
Phathom Pharmaceuticals Inc   78.32 %$ 66.355  Millions$ 84.722  Millions
Eton Pharmaceuticals Inc   76.48 %$ 44.301  Millions$ 57.925  Millions
Pfizer Inc  75.71 %$ 12,555.000  Millions$ 16,583.000  Millions
Harrow Inc   75.43 %$ 74.903  Millions$ 99.297  Millions
Abbvie Inc   75.38 %$ 13,119.000  Millions$ 17,404.000  Millions
Lifevantage Corp  75.35 %$ 27.969  Millions$ 37.117  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.